EPIGENETIC AND MRNA PROFILING OF STRIATOPALLIDAL NEURONS IN HUNTINGTON'S DISEASE
EPIGENETIC AND MRNA PROFILING OF STRIATOPALLIDAL NEURONS IN HUNTINGTON'S DISEASE
批准号:
9245425
负责人:
Hiroko Yano
金额:
$19.06万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2018-08-31
关键词:
Affinity ChromatographyAgeAtrophicAutomobile DrivingBiologicalBrainCellsChIP-seqChromatinCompanionsCorpus striatum structureDataDevelopmentDiseaseDisease ProgressionDisease modelDissociationDopamine D2 ReceptorEpigenetic ProcessEventFibroblastsFractionationGene ExpressionGene Expression ProfilingGene Expression RegulationGenesGenetic TranscriptionGoalsHistonesHumanHuntington DiseaseHuntington geneImpaired cognitionInterneuronsMessenger RNAMolecularMovementMusNerve DegenerationNeurodegenerative DisordersNeuronsNuclearNuclear RNAPathogenesisPhenotypePlayPopulationPost-Translational Protein ProcessingProteinsRNARNA purificationResearchRibosomal ProteinsRibosomesRiskRoleSequence AnalysisSorting - Cell MovementStructureSystemTechniquesTechnologyTherapeuticToxic effectTranslatingWild Type Mouseabstractingcell typedifferential expressioneffective therapyepigenetic regulationepigenomegene discoveryhistone modificationin vivoinsightmouse modelmutantnervous system disorderneuron lossneurotoxicitynew therapeutic targetnext generation sequencingnovel therapeuticspolyglutaminepreventpromotertherapeutic targettranscriptometranscriptome sequencingwhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Abstract
Huntington's disease (HD) is a devastating and fatal neurodegenerative disease with no effective treatments to
date. Progressive striatal atrophy caused by the selective loss of GABAergic medium spiny neurons (MSNs) is
a hallmark of HD. Transcriptional dysregulation occurs early in the course of HD progression and is thought to
play a central role in this disease. Emerging evidence suggests that epigenetic mechanisms, including
posttranslational modification of histones, play important roles in the transcriptional dysregulation observed in
HD. A significant gap in our current understanding of this disease is the lack of an integrated epigenetic and
transcriptional landscape in the at-risk neuronal subpopulation, the striatopallidal MSN. The long-term goal of
this proposal is to discover therapeutic strategies that target early epigenetic and transcriptional abnormalities
in a specific, disease-relevant neuronal subpopulation to prevent neurodegeneration. The fundamental
objective of this proposal is to identify and integrate the epigenome and transcriptome specifically in
striatopallidal MSNs in HD model mice in vivo. The two specific aims are as follows: 1) To identify key HD-
associated mRNA changes in striatopallidal MSNs; and 2) To identify key HD-associated epigenetic changes
in striatopallidal MSNs in HD. The proposed research overcomes current limitations of gene expression and
chromatin analysis in normal and diseased neurons in vivo by using a combination of a recently developed
translating ribosome affinity purification (TRAP) technique and next-generation sequencing. Unique HD mouse
models, which express genetically-tagged ribosomes specifically in striatopallidal MSNs, will be utilized for the
isolation of cell type-specific mRNA and chromatin from brain for RNA-sequencing (seq) and ChIP-seq
analysis. Furthermore, among the differentially regulated genes discovered in the first aim, critical genes and
upstream regulatory mechanisms that contribute to cellular phenotypes caused by the mutant HD protein will
be identified using physiologically relevant and complementary mouse and human neuronal culture systems.
Identification of key alterations in the epigenetic and transcriptional landscape in the at-risk neuronal
subpopulation in HD will provide fundamental insights into important epigenetic mechanisms that drive
transcriptional dysregulation and subsequent neurodegeneration. Such findings are expected to have an
important positive impact in the field of neurodegenerative disease since identified molecular changes will likely
provide novel therapeutic targets for HD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of DNA methyltransferases in Huntington's disease
-
批准号:10405542
-
项目类别:
-
资助金额:$40.85万
-
财政年份:2019
-
负责人:Hiroko Yano
-
依托单位:
Role of DNA methyltransferases in Huntington's disease
-
批准号:10160970
-
项目类别:
-
资助金额:$42.72万
-
财政年份:2019
-
负责人:Hiroko Yano
-
依托单位:
Role of DNA methyltransferases in Huntington's disease
-
批准号:9919649
-
项目类别:
-
资助金额:$42.72万
-
财政年份:2019
-
负责人:Hiroko Yano
-
依托单位:
Role of DNA methyltransferases in Huntington's disease
-
批准号:10631033
-
项目类别:
-
资助金额:$37.29万
-
财政年份:2019
-
负责人:Hiroko Yano
-
依托单位:
Polycomb-mediated epigenetic mechanisms in neurodegeneration and aging brain
-
批准号:8582651
-
项目类别:
-
资助金额:$12.92万
-
财政年份:2009
-
负责人:Hiroko Yano
-
依托单位:
Polycomb-mediated epigenetic mechanisms in neurodegeneration and aging brain
-
批准号:8260339
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Hiroko Yano
-
依托单位:
Polycomb-mediated epigenetic mechanisms in neurodegeneration and aging brain
-
批准号:7644094
-
项目类别:
-
资助金额:$13.18万
-
财政年份:2009
-
负责人:Hiroko Yano
-
依托单位:
Polycomb-mediated epigenetic mechanisms in neurodegeneration and aging brain
-
批准号:8254662
-
项目类别:
-
资助金额:$13.18万
-
财政年份:2009
-
负责人:Hiroko Yano
-
依托单位:
Polycomb-mediated epigenetic mechanisms in neurodegeneration and aging brain
-
批准号:7781332
-
项目类别:
-
资助金额:$13.18万
-
财政年份:2009
-
负责人:Hiroko Yano
-
依托单位:
Polycomb-mediated epigenetic mechanisms in neurodegeneration and aging brain
-
批准号:8447487
-
项目类别:
-
资助金额:$12.66万
-
财政年份:2009
-
负责人:Hiroko Yano
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: